Summary

Overview
Global hazardous drug administration market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031.
Hazardous drug administration is the process of handling, preparing, dispensing, and administering medications that are considered hazardous due to their inherent toxicity, carcinogenicity, teratogenicity, reproductive toxicity, or other properties that harm human health and the environment. Chemotherapy agents, immunosuppressants, antivirals, hormones, and some biological agents are among the medications available.
Ensuring patient safety during hazardous drug administration entails precise dosing, monitoring for side effects, and adhering to treatment standards. Healthcare practitioners must adhere to established processes to reduce the likelihood of prescription errors and hazardous reactions.
Market Dynamics: Drivers & Restraints
Growing Awareness of Occupational Hazards
Growing awareness of occupational hazards is expected to drive the market growth. As healthcare professionals become more aware of the potential risks of exposure to hazardous medications, there is a greater demand for safety measures that reduce such hazards. As a result, healthcare facilities will require more closed system transfer devices (CSTDs), negative pressure rooms, personal protective equipment (PPE), and suitable ventilation systems.
Regulatory organizations and healthcare institutions are focusing more on protecting healthcare workers from occupational dangers. This leads to more difficult laws and procedures for dealing with dangerous pharmaceuticals, which drives the demand for technology and equipment that assure safe administration.
The increased awareness of occupational hazards needs improved training and education programs for healthcare personnel on safe drug handling procedures. This fuels the market for training modules, educational materials, and even specialist training institutions focused on hazardous drug safety. Thus, the above factors are expected to drive the market growth.
High cost of Closed System Transfer Devices (CSTDs)
Closed system transfer devices serve as specialized tools for reducing healthcare personnel' exposure to hazardous medications. While they considerably improve safety, CSTDs can be costly to purchase and implement, thereby limiting their use in some healthcare facilities, particularly in low- and middle-income nations.
For more details on this report – Request for Sample
Segment Analysis
The global hazardous drug administration market is segmented based on systems, drug type, devices, drug form, and region.
Closed-System Drug Transfer Devices (CSTDs) segment is expected to dominate the market growth
Closed-system drug transfer devices (CSTDs) are likely to dominate the hazardous drug administration market due to several significant advantages and an increased regulatory focus on safety. CSTDs are intended to reduce the exposure of healthcare workers and veterinarians to hazardous medications during preparation, delivery, and disposal. Airtight connections and barriers prevent drug vapors or aerosols from escaping, lowering the danger of inhalation or skin contact.
To protect healthcare personnel and patients, regulatory bodies such as the United States Food and Drug Administration and the European Medicines Agency (EMA) have rigorous standards for handling dangerous medications. Many of these guidelines encourage or require the use of CSTDs to guarantee compliance with safety standards.
Geographical Analysis
North America is expected to hold a significant position in the hazardous drug administration market share
North America is expected to hold a dominant position in the hazardous drug administration market due to the advanced healthcare infrastructure in the region, high incidence of chronic diseases, and technological innovation.
North America has a well-developed healthcare infrastructure, including robust hospital systems, clinics, and veterinary facilities. These institutions prioritize patient safety and healthcare worker safety, which has resulted in considerable investments in technologies such as closed-system drug transfer devices (CSTDs) and biological safety cabinets (BSCs) for safer medication administration.
Cancer, autoimmune disorders, and viral diseases are common in the region, necessitating the use of hazardous medications such as chemotherapeutic agents and immunosuppressants for treatment. This involves widespread usage of hazardous medication administration procedures in the healthcare and veterinary sectors. Thus, the above factors are expected to hold the region in the dominant position.
Market Segmentation
By Systems
• Closed
• Non-Closed
By Drug Type
• Hazardous Drugs
• Antimitotics
By Devices
• Luer Lock
• CLick-to-Lock
• Push-Turn-Push
• Color-to-Color Alignment
• Others
By Drug Form
• Liquid
• Solid
By Drug Form
• Gravity
• Pump
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include ICU Medical, Equashield, LLC, Simplivia Healthcare Ltd., Becton & Dickinson, Baxter International, Vygon SAS, JMS Co., Ltd., B. Braun Medical Inc., Yukon Medical, and Codan Medical among others.
Why Purchase the Report?
• To visualize the global hazardous drug administration market segmentation based on systems, drug type, devices, drug form, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of hazardous drug administration market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global hazardous drug administration market report would provide approximately 53 tables, 47 figures and 176 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

Table of Contents
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Systems
3.2. Snippet by Drug Type
3.3. Snippet by Devices
3.4. Snippet by Drug Form
3.5. Snippet by Perfusion Pressure
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Ri Growing Awareness of Occupational Hazards
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. High cost of closed system transfer devices (CSTDs)
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. By Systems
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Systems
6.1.2. Market Attractiveness Index, By Systems
6.2. Closed*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Non-Closed
7. By Drug Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type
7.2. Hazardous Drugs*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Antimitotic Drugs
8. By Devices
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices
8.1.2. Market Attractiveness Index, By Devices
8.2. Luer Lock*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. CLick-to-Lock
8.4. Push-Turn-Push
8.5. Color-to-Color Alignment
8.6. Others
9. By Drug Form
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Form
9.1.2. Market Attractiveness Index, By Drug Form
9.2. Liquid*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Solid
10. By Perfusion Pressure
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Perfusion Pressure
10.1.2. Market Attractiveness Index, By Perfusion Pressure
10.2. Gravity*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Pump
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Systems
11.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.2.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices
11.2.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Form
11.2.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Perfusion Pressure
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.3.1. U.S.
11.2.3.2. Canada
11.2.3.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Systems
11.3.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.3.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Form
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.4.1. Germany
11.3.4.2. UK
11.3.4.3. France
11.3.4.4. Italy
11.3.4.5. Spain
11.3.4.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Systems
11.4.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.4.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Form
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.4.1. Brazil
11.4.4.2. Argentina
11.4.4.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Systems
11.5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.5.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Form
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.4.1. China
11.5.4.2. India
11.5.4.3. Japan
11.5.4.4. Australia
11.5.4.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Systems
11.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.6.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices
11.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Form
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. ICU Medical*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Equashield, LLC
13.3. Simplivia Healthcare Ltd.
13.4. Becton & Dickinson
13.5. Baxter International
13.6. Vygon SAS
13.7. JMS Co., Ltd.
13.8. B. Braun Medical Inc.
13.9. Yukon Medical
13.10. Codan Medical
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us